Zoe McQuilten, Stephane Heritier, Lucy Fox, Vanessa Fox, Lauren Young, Piers Blombery, Ilona Cunningham, Jennifer Curnow, Alisa Higgins, Devendra K Hiwase, Robin Filshie, Frank Firkin, Paul Lacaze, Kylie Mason, Anthony K Mills, Dominic Pepperell, Sushrut Patil, William Stevenson, Jeff Szer, Neil Waters, Kate Wilson, Stephen Ting, Erica Wood
INTRODUCTION: Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and ciclosporin is standard of care for patients with severe aplastic anaemia (sAA) not eligible or suitable for allogeneic stem cell transplant. While patients respond to IST, few achieve complete responses and a significant proportion are refractory or relapse. The addition of eltrombopag, a thrombopoietin-receptor agonist (TPO-A), to IST has been shown to improve haematological responses in sAA. Avatrombopag is a second-generation TPO-A with potential advantages over eltrombopag...
January 18, 2024: BMJ Open